A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This phases Ⅲ trials is divided into two stages,Ⅲa and Ⅲb.The aim of Ⅲa is to evaluate the
optimal dosing dose of genetically modified recombinant human IL-11 (mIL-11) in a multicenter
randomized self-control trial involving 60 cancer patients undergoing chemotherapy.The aim of
Ⅲb is to evaluate the efficacy and safety of genetically modified recombinant human IL-11
(mIL-11), using rhIL-11 as an active control, in a multicenter randomized trial involving 240
cancer patients undergoing chemotherapy.